As seen in Fig 5C–E, treatment with GLS1 siRNA‐DOPC in Gln‐independent IGROV1 tumor‐bearing mice did not affect tumor volume or deep tumor infiltration through the muscle layers compared to control siRNA treatment. This evidence concerns the gene GLS and neoplasm.